Last €25.32 EUR
Change Today -0.384 / -1.49%
Volume 0.0
MZN On Other Exchanges
Symbol
Exchange
Munich
As of 1:01 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MZN) Snapshot

Open
€25.90
Previous Close
€25.70
Day High
€25.90
Day Low
€25.32
52 Week High
01/26/15 - €26.00
52 Week Low
10/13/14 - €15.76
Market Cap
1.7B
Average Volume 10 Days
6.3
EPS TTM
--
Shares Outstanding
65.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MZN)

medicines company (MZN) Related Businessweek News

No Related Businessweek News Found

medicines company (MZN) Details

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise Fibrocaps, which is used as an aid to stop bleeding during surgery; RPX-602 for the treatment of infections; MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and ALN-PCSsc, a subcutaneously administered RNA interference therapeutic for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular and neurocritical care; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaborations with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Founded in 1996

medicines company (MZN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MZN) Key Developments

The Medicines Company Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

The Medicines Company Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

The Medicines Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:30 AM

The Medicines Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 08:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Clive A. Meanwell, Chairman and Chief Executive Officer.

The Medicines Company Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

The Medicines Company announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net revenue increased by 3.2% to $191.0 million from $185.0 million in the fourth quarter of 2013. Net loss was $5.3 million, or $0.08 per share, compared with net income of $1.2 million, or $0.02 per share for the fourth quarter of 2013. Adjusted net income was $13.5 million, or $0.20 per share compared to adjusted net income of $15.4 million, or $0.23 per share for the fourth quarter 2013. Loss from operations was $34,781,000 compared to $15,862,000 a year ago. Loss before income taxes was $5,192,000 compared $14,717,000 a year ago. For the full year, the company’s net revenue increased by 5.3% to $724.4 million in 2014, from $687.9 million in 2013. Net loss was $32.2 million, or $0.50 per share, compared with net income of $15.5 million, or $0.25 per share in 2013. Adjusted net income was $67.8 million, or $1.02 per share compared to adjusted net income of $91.9 million, or $1.50 per share in 2013. Loss from operations was $64,567,000 compared to income from operations of $13,191,000 a year ago. Loss before income taxes was $39,185,000 compared income before income taxes of $16,620,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MZN:GR €25.32 EUR -0.384

MZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.15 USD +0.48
CR Bard Inc $169.14 USD -1.80
CryoLife Inc $10.48 USD -0.24
Integra LifeSciences Holdings Corp $60.01 USD +1.78
Medicure Inc C$2.07 CAD +0.07
View Industry Companies
 

Industry Analysis

MZN

Industry Average

Valuation MZN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.